Prasol Chemicals Q1 FY27: IPO debut, record quarter, and the next capex cycle

Prasol Chemicals entered the public markets on 16 September 2026, and it did so with a quarter that management called its highest ever on many key parameters. In Q1 FY27, revenue rose to INR 433.6 crores, up 36 percent year on year, supported by steady volume growth, better realisations, and an improving product mix. Profitability scaled faster than revenue. EBITDA more than doubled to INR 90.3 crores, up 122 percent year on year, and PAT grew 151 percent to INR 61.0 crores.

The numbers mattered on their own, but they also set the tone for what the company wants investors to focus on after listing. The management message framed the quarter as proof that Prasol’s diversified specialty chemicals model can convert higher utilisation and a richer product mix into operating leverage. It also highlighted a key operational pivot. The Mahad facility recorded its best ever quarterly production and improved capacity utilisation, which management linked to a turnaround in profitability and the step-up in EBITDA margin.

Two caveats sit inside the headline margins. The company disclosed that Q1 FY27 gross profit included a sharp increase in average selling price due to geopolitical-led supply chain issues, adding about INR 25 crores, and a positive INR 0.92 crores impact from foreign currency fluctuations. Management expects normalisation in coming quarters. Investors, therefore, need to separate the structural margin improvement, driven by product mix and Mahad utilisation, from the temporary benefit from pricing dislocations.

A record quarter built on mix, utilisation, and a pricing tailwind

Prasol’s Q1 FY27 revenue performance was described as a blend of volumes, better product mix, and higher realisations. Demand remained healthy across acetone-based and phosphorous-based products despite external challenges. Domestic sales grew strongly in value and volume, backed by demand for value-added products. Exports grew year on year, but shipments were held back by geopolitical tensions related to the West Asia conflict.

The profitability jump was the defining feature. EBITDA margin expanded to 20.8 percent in Q1 FY27 from 12.7 percent in Q1 FY26. That expansion came alongside a rise in gross margin to 37.9 percent from 30.0 percent. The company’s longer-term charted trend shows a structured uplift in margins over the years, with gross margin improving from an average of 23 percent in FY11 to FY15, to 26 percent in FY16 to FY19, and to 30 percent in FY20 to FY26. Management linked this to increased capacity under secondary and tertiary derivatives, the addition of products such as ZDDP, IPH and PPS, and the commissioning of cogeneration in 2019.

But Q1 FY27 sits above that trend line. The company explicitly attributed about INR 25 crores of gross profit to higher average selling prices caused by geopolitical-led supply chain disruptions, plus INR 0.92 crores from foreign currency fluctuations. The implication is that Q1 margins should not be extrapolated mechanically. The more durable question is whether the company can sustain higher throughput at Mahad and keep shifting the portfolio toward secondary and tertiary derivatives in both acetone and phosphorus value chains.

Financial summary

The operating story: Mahad improves, and the portfolio moves up the chain

Prasol positions itself as a diversified specialty chemical company with deeper chemistry across forward and backward integration. It manufactures more than 150 specialty chemical products, serves more than 1,600 customers, exports to more than 65 countries, and operates two manufacturing units at Khopoli and Mahad. Installed capacity stood at 98,644 MTPA as at FY26, split between Khopoli at 78,784 MTPA and Mahad at 19,860 MTPA. Both sites have spare land available for expansion, with 11.98 acres at Khopoli and 18.4 acres at Mahad.

Within that footprint, Mahad has been a swing factor in the recent margin profile. The company’s historical P&L table notes that losses on account of Mahad reduced from INR 14.9 crores in FY24 to INR 3.9 crores in FY26. It also provides EBITDA excluding Mahad losses, suggesting that the underlying profitability trajectory would have looked better without the drag. Q1 FY27 management commentary points to a more decisive change, stating that improved utilisation at Mahad led to a turnaround in profitability and contributed to the overall EBITDA margin uptick.

The product story is also about moving from platform derivatives to higher value downstream offerings. The presentation describes a value chain that begins with key raw materials and platforms, moving through primary, secondary and tertiary derivatives. It highlights acetone-based and phosphorous-based product lines, and notes that product mix improved as secondary and tertiary derivatives grew in both value chains in Q1 FY27.

Prasol’s diversification is not limited to chemistry. Revenue mix in FY26 was 73 percent domestic and 27 percent exports. Exports were split across Europe at 12 percent, APAC at 7 percent, Americas at 5 percent, and others at 3 percent. By product, FY26 revenue mix was 43 percent acetone based, 38 percent phosphorous based, and 19 percent others. The company also disclosed that top 10 customers contribute not more than about 25 percent, helping reduce concentration risk.

A structural feature in specialty chemicals is the approval cycle. Prasol states that customer approvals typically take one to four years, which can slow the pace of new account wins but can also deepen customer stickiness once products are qualified. The company underlines this by referencing multi-year relationships across industries such as performance chemicals, pharmaceuticals, agrochemicals, and home and personal care, alongside a pattern of increasing the number of products supplied to existing customers over time.

Capital allocation: two-phase expansion and how it links to growth goals

After the IPO listing, the company set out a clear framework for what comes next: capacity expansion in two phases, debottlenecking existing capacities, improving operational efficiencies, ramping production at Mahad, enhancing export presence, and keeping R&D central to new product lines.

The capex plan is split into two parts. Phase I is an expansion in existing products estimated at INR 250 to 300 crores, including INR 50 to 60 crores for land and infrastructure development. This is planned through multiple sub-phases over the next two years. At peak utilisation, management expects incremental revenue potential of INR 500 to 550 crores from Phase I. The capacity bridge shown in the presentation takes existing capacity of 98,844 MTPA and adds 60,000 MTPA in Phase I, for total capacity of 1,58,844 MTPA by FY29. FY26 utilisation was stated at 70 to 72 percent.

Phase II targets new R&D products, also estimated at INR 250 to 300 crores, again including INR 50 to 60 crores in infrastructure development. Products have been identified, and site preparation and regulatory approvals are in progress. Management expects capex spending for Phase II to begin in H2 FY28. Funding for capex is expected through internal accruals and debt.

The company also stated an aspiration to reach INR 2,800 to 3,000 crores of revenue over the next five years. That ambition needs to be read alongside both the capacity expansion plan and the R&D pipeline. The R&D section indicates 40 products in the pipeline, with 13 new products commercialised in three years, supported by a 37-member R&D team that includes 4 PhDs and 25 chemists. The company is also in the process of developing a separate application testing laboratory and collaborates with academic institutions.

Management guidance for FY27 sets near-term expectations. The chairman’s message states an expected FY27 revenue of INR 1,550 to 1,650 crores, with EBITDA of INR 240 to 250 crores, excluding price fluctuations due to geopolitical-led supply chain issues and foreign exchange gains or losses.

Market context, but with execution risks in plain sight

The presentation leans on industry growth and tailwinds as supportive context. It lists expected market CAGR of 8 percent for the Indian acetone derivative market and 10 percent for the Indian phosphorous derivative market for FY26 to FY29P, with data sourced from a CARE report. It also points to tailwinds such as China plus one sourcing, a European structural crisis linked to higher energy costs, and rising domestic consumption driven by urbanisation and infrastructure.

Still, the company’s own slides list a long run of external disruptions: Covid-19, the Russia-Ukraine war, global inventory destocking, the Mahad shutdown in FY24, tariff war dynamics, global slowdown, West Asia conflict, and broader supply chain challenges. Q1 FY27 itself benefitted from supply chain disruption through higher pricing. That is a reminder that earnings can be influenced by factors that reverse quickly.

This is where the operational story becomes more important than the macro story. If higher Mahad utilisation is sustained, and if product mix continues to shift toward secondary and tertiary derivatives, the company has a plausible path to better margins even when pricing normalises. The historical numbers suggest this is not only theoretical. FY26 gross margin was 30.7 percent and EBITDA margin was 11.3 percent, up from 26.1 percent and 6.9 percent in FY24. PAT margin improved to 6.7 percent in FY26 from 2.1 percent in FY24.

Balance sheet metrics in the presentation show a company that has operated with moderate leverage. Net debt to equity was 0.19x in FY26, and adjusted ROCE was 22.4 percent. Working capital days were 50 in FY26, higher than FY25 at 37, and the FY26 balance sheet shows trade receivables at INR 278.7 crores and inventories at INR 153.2 crores. In a specialty chemical business with multiple end markets and export exposure, working capital discipline can become a differentiator as the company scales.

The IPO proceeds section provides a simple deployment plan. Net proceeds of INR 76.4 crores are allocated to repayment or prepayment of borrowings of INR 60.0 crores and general corporate purposes of INR 16.4 crores, all slated for deployment during fiscal 2027. The reduction in borrowings, even if modest relative to the broader capex ambitions, supports financial flexibility at the start of the expansion cycle.

What to track from here

Prasol’s first quarter as a listed company combined strong growth with a margin spike that included a one-off tailwind. The most important signal was not only the 36 percent revenue growth or the 151 percent jump in PAT, but the operational improvement at Mahad and the continued shift toward higher value derivatives.

The near-term investor task is to watch for normalised margins and ask whether the company can still hold a step-up versus FY26 levels. Management has already guided that the pricing benefit from supply chain issues should normalise in coming quarters. If the business can sustain higher utilisation, keep expanding secondary and tertiary products, and execute Phase I capex on schedule, the company’s own roadmap suggests a multi-year growth runway.

In that context, Q1 FY27 reads like a statement of intent. It shows what operating leverage can look like when capacity, mix, and pricing move in the same direction. The next few quarters will show how much of that leverage is structural. The theme for investors is disciplined execution: getting Mahad fully stabilised, funding expansion without stressing the balance sheet, and converting a 40-product R&D pipeline into commercial revenues over time.